220 related articles for article (PubMed ID: 17639741)
1. Respiratory syncytial virus: different criteria for palivizumab use in different areas?
Mitchell I
South Med J; 2007 Jul; 100(7):661-2. PubMed ID: 17639741
[No Abstract] [Full Text] [Related]
2. Respiratory syncytial virus: seasonal data for regions of Florida and implications for palivizumab.
Bauman J; Eggleston M; Oquist N; Malinoski F
South Med J; 2007 Jul; 100(7):669-76. PubMed ID: 17639745
[TBL] [Abstract][Full Text] [Related]
3. Response to respiratory synctial virus.
Hampp C; Winterstein AG
South Med J; 2008 Feb; 101(2):212-3; author reply 213-4. PubMed ID: 18364631
[No Abstract] [Full Text] [Related]
4. [Prevention of respiratory syncytial virus infections with palivizumab].
Ellingsen BB; Aase SA; Øymar K
Tidsskr Nor Laegeforen; 2003 Apr; 123(7):941-3. PubMed ID: 12737068
[No Abstract] [Full Text] [Related]
5. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.
Warren A; Langley JM; Thomas W; Scott J
Can J Cardiol; 2007 May; 23(6):463-6. PubMed ID: 17487291
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of passive immunisation against respiratory syncytium virus in a group of premature infants with birth weight below 1000 grams].
Korbal P; Mikołajczak A; Szymański W
Ginekol Pol; 2003 Oct; 74(10):1154-9. PubMed ID: 14669411
[TBL] [Abstract][Full Text] [Related]
7. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus.
Meissner HC; Bocchini JA; Brady MT; Hall CB; Kimberlin DW; Pickering LK
Pediatrics; 2009 Dec; 124(6):1676-9. PubMed ID: 19948632
[No Abstract] [Full Text] [Related]
8. A review of palivizumab and emerging therapies for respiratory syncytial virus.
Shadman KA; Wald ER
Expert Opin Biol Ther; 2011 Nov; 11(11):1455-67. PubMed ID: 21831008
[TBL] [Abstract][Full Text] [Related]
9. Strategies for preventing respiratory syncytial virus.
Forbes M
Am J Health Syst Pharm; 2008 Dec; 65(23 Suppl 8):S13-9. PubMed ID: 19020197
[TBL] [Abstract][Full Text] [Related]
10. Immunoprophylaxis for respiratory syncytial virus.
Sánchez PJ
Pediatr Infect Dis J; 2002 May; 21(5):473-8. PubMed ID: 12150195
[No Abstract] [Full Text] [Related]
11. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion.
Meissner HC; Welliver RC; Chartrand SA; Law BJ; Weisman LE; Dorkin HL; Rodriguez WJ
Pediatr Infect Dis J; 1999 Mar; 18(3):223-31. PubMed ID: 10093942
[No Abstract] [Full Text] [Related]
12. RSV disease--is there a role for prevention?
Lenney W
Respir Med; 2001 Mar; 95(3):170-2. PubMed ID: 11266232
[No Abstract] [Full Text] [Related]
13. Respiratory syncytial virus: concerns and control.
McCarthy CA; Hall CB
Pediatr Rev; 2003 Sep; 24(9):301-9. PubMed ID: 12949266
[No Abstract] [Full Text] [Related]
14. New strategies for control of respiratory syncytial virus infection.
Nokes JD; Cane PA
Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
Mahadevia PJ; Malinoski FJ
Arch Pediatr Adolesc Med; 2007 May; 161(5):519-20; author reply 520. PubMed ID: 17485634
[No Abstract] [Full Text] [Related]
16. [RSV-prophylaxis--to whom?].
Lossius K
Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2494. PubMed ID: 11070982
[No Abstract] [Full Text] [Related]
17. Use of palivizumab in Germany: data from 2002-2007.
Simon A; Nowak H; Sterz R
Klin Padiatr; 2011 Sep; 223(5):292-8. PubMed ID: 21509705
[TBL] [Abstract][Full Text] [Related]
18. Management of respiratory syncytial virus infection.
Kimpen JL
Curr Opin Infect Dis; 2001 Jun; 14(3):323-8. PubMed ID: 11964851
[TBL] [Abstract][Full Text] [Related]
19. Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals.
Murray J; Saxena S; Sharland M
Arch Dis Child; 2014 May; 99(5):469-73. PubMed ID: 24464977
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants.
Boeckh M; Berrey MM; Bowden RA; Crawford SW; Balsley J; Corey L
J Infect Dis; 2001 Aug; 184(3):350-4. PubMed ID: 11443562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
